News

Jenburkt Pharmaceuticals announced that the 41th Annual General Meeting(AGM) of the company will be held on 4 September 2026.

Jenburkt Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 5 May 2026, inter alia, have recommended the final dividend of Rs 20.7 per equity Share (i.e. 207%) , subject to the approval of the shareholders.

Net profit of Jenburkt Pharmaceuticals rose 27.05% to Rs 10.85 crore in the quarter ended March 2026 as against Rs 8.54 crore during the previous quarter ended March 2025. Sales rose 8.72% to Rs 44.63 crore in the quarter ended March 2026 as against Rs 41.05 crore during the previous quarter ended March 2025.For the full year,net profit rose 8.36% to Rs 34.74 crore in the year ended March 2026 as against Rs 32.06 crore during the previous year ended March 2025. Sales rose 11.24% to Rs 168.74 crore in the year ended March 2026 as against Rs 151.69 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales44.6341.05 9 168.74151.69 11 OPM %31.9326.46 -25.9226.63 - PBDT18.4712.63 46 53.5846.66 15 PBT17.6611.84 49 50.4743.93 15 NP10.858.54 27 34.7432.06 8 Powered by Capital Market - Live News

Jenburkt Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 5 May 2026.

Net profit of Jenburkt Pharmaceuticals declined 8.91% to Rs 5.93 crore in the quarter ended December 2025 as against Rs 6.51 crore during the previous quarter ended December 2024. Sales rose 16.62% to Rs 43.02 crore in the quarter ended December 2025 as against Rs 36.89 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales43.0236.89 17 OPM %17.2723.94 - PBDT9.1310.30 -11 PBT8.309.52 -13 NP5.936.51 -9 Powered by Capital Market - Live News